{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:52:50Z","timestamp":1789876370164,"version":"4.0.1"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Immunocompromised patients with B-cell depletion agents are at risk for persistence and\/or severe SARS-COV-2 infection. We describe a case series of 21 COVID-19 patients under B cell depletion therapy, mostly treated with a combined therapy based on intravenous remdesevir (RDV) and steroid associated with SARS-CoV-2 monoclonal antibodies against Spike glycoprotein and\/or hyper-immune convalescent plasma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a single-center longitudinal study. We retrospectively enrolled a total number of 21 B-cell depleted consecutive hospitalized patients with COVID-19 at the Lazzaro Spallanzani National Institute for Infectious Diseases, Rome, Italy, from November 2020 to December 2021. Demographic characteristics, medical history, clinical presentation, treatment, adverse drug reactions, and clinical and virological outcome were collected for all patients. In a subgroup, we explore immune T cells activation, T cells specific anti-SARS-COV-2 response, and neutralizing antibodies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-one inpatients with B-cell depletion and SARS-COV-2 infection were enrolled. A median of 1 B cells\/mm\n                      <jats:sup>3<\/jats:sup>\n                      was detected. Eighteen patients presented hypogammaglobulinemia. All patients presented interstitial pneumonia treated with intravenous RDV and steroids. Sixteen patients were treated with monoclonal antibodies against SARS-CoV-2 Spike protein, four patients were treated with SARS-CoV-2 hyper-immune convalescent plasma infusion, and three patients received both treatments. A variable kinetic of T cell activation returning to normal levels at Day 30 after immunotherapy infusion was observed. All treated patients recovered.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In COVID-19 immunosuppressed subjects, it is mandatory to establish a prompt, effective, and combined multi-target therapy including oxygen, antiviral, steroid, and antibody-based therapeutics, tailored to the patient\u2019s clinical needs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2022.911339","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T07:50:24Z","timestamp":1674805824000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway"],"prefix":"10.3389","volume":"13","author":[{"given":"Alessandra","family":"D\u2019Abramo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Maffongelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Beccacece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Agrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Cimini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Colavita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Letizia","family":"Giancola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Cavasio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Nicastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Spallanzani COVID-19 Case Investigation Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-00092-2","article-title":"B Cell Depletion Therapies in Autoimmune Disease: Advances and Mechanistic Insights","volume":"20","author":"Lee","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cellimm.2006.02.005","article-title":"B Cells as Antigen Presenting Cells","volume":"238","author":"Rodr\u00edguez-Pinto","year":"2005","journal-title":"Cell Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1998.16.8.2825","article-title":"Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"JCO"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1612872","article-title":"Risk of Tuberculosis Reactivation Associated With Traditional Disease Modifying Anti-Rheumatic Drugs and Non-Anti-Tumor Necrosis Factor Biologics in Patients With Rheumatic Disorders and Suggestion for Clinical Practice","volume":"18","author":"Cantini","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(20)30251-9","article-title":"Clinical Characteristics and Risk Factors Associated With COVID-19 Severity in Patients With Haematological Malignancies in Italy: A Retrospective, Multicentre, Cohort Study","volume":"7","author":"Passamonti","year":"2020","journal-title":"Lancet Haematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0869-5","article-title":"Temporal Dynamics in Viral Shedding and Transmissibility of COVID-19","volume":"26","author":"He","year":"2020","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25952","article-title":"Prolonged SARS-CoV-2 RNA Shedding: Not a Rare Phenomenon","volume":"92","author":"Li","year":"2020","journal-title":"J Med Virol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11091663","article-title":"Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews","volume":"11","author":"Franchini","year":"2021","journal-title":"Diagnostics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14760584.2021.1932475","article-title":"Potential Use of Convalescent Plasma for SARS-CoV-2 Prophylaxis and Treatment in Immunocompromised and Vulnerable Populations","author":"Focosi","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.04.068","article-title":"Prolonged and Severe SARS-CoV-2 Infection in Patients Under B-Cell-Depleting Drug Successfully Treated: A Tailored Approach","volume":"107","author":"D\u2019Abramo","year":"2021","journal-title":"Int J Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.jaci.2021.10.031","article-title":"Treatment of Chronic or Relapsing COVID-19 in Immunodeficiency","volume":"149","author":"Brown","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(21)00251-4","article-title":"Humoral and Cellular Responses to mRNA Vaccines Against SARS-CoV-2 in Patients With a History of CD20 B-Cell-Depleting Therapy (RituxiVac): An Investigator-Initiated, Single-Centre, Open-Label Study","volume":"3","author":"Moor","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0836-7","article-title":"COVID-19 in Persons With Haematological Cancers","volume":"34","author":"He","year":"2020","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(20)30270-8","article-title":"B-Cell Depletion With Rituximab in the COVID-19 Pandemic: Where do We Stand","volume":"2","author":"Mehta","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008423","article-title":"Convalescent Plasma Therapy for B-Cell\u2013Depleted Patients With Protracted COVID-19","volume":"136","author":"Hueso","year":"2020","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2007764","article-title":"Remdesivir for the Treatment of Covid-19 \u2014 Final Report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2119657","article-title":"Early Outpatient Treatment for Covid-19 With Convalescent Plasma","author":"Sullivan","year":"2022","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jaci.2020.04.043","article-title":"Development of Passive Immunity Against SARS-CoV-2 for Management of Immunodeficient Patients\u2014a Perspective","volume":"146","author":"Hammarstr\u00f6m","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010029","article-title":"Analysis of Immune Escape Variants From Antibody-Based Therapeutics Against COVID-19: A Systematic Review","volume":"23","author":"Focosi","year":"2021","journal-title":"IJMS"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.911339\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T07:50:26Z","timestamp":1674805826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.911339\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,27]]},"references-count":19,"alternative-id":["10.3389\/fimmu.2022.911339"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.911339","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,27]]},"article-number":"911339"}}